2022
Asparagine Metabolism in Tumors Is Linked to Poor Survival in Females with Colorectal Cancer: A Cohort Study
Shen X, Cai Y, Lu L, Huang H, Yan H, Paty PB, Muca E, Ahuja N, Zhang Y, Johnson CH, Khan SA. Asparagine Metabolism in Tumors Is Linked to Poor Survival in Females with Colorectal Cancer: A Cohort Study. Metabolites 2022, 12: 164. PMID: 35208238, PMCID: PMC8875032, DOI: 10.3390/metabo12020164.Peer-Reviewed Original ResearchRecurrence-free survivalOverall survivalColorectal cancer prognosisPoor overall survivalPrimary tumor tissuesTumor metabolomeUnique metabolite profilesCohort studyCRC patientsCRC treatmentFemale patientsPoor prognosisColorectal cancerPrognostic disadvantagePatient outcomesPoor survivalSurgical colectomySex-specific differencesCox proportionalEleven metabolitesUntargeted metabolomics analysisCancer prognosisStage ITumor tissueSignificant sex differences
2020
Tumor Tissue-Specific Biomarkers of Colorectal Cancer by Anatomic Location and Stage
Cai Y, Rattray NJW, Zhang Q, Mironova V, Santos-Neto A, Muca E, Vollmar AKR, Hsu KS, Rattray Z, Cross JR, Zhang Y, Paty PB, Khan SA, Johnson CH. Tumor Tissue-Specific Biomarkers of Colorectal Cancer by Anatomic Location and Stage. Metabolites 2020, 10: 257. PMID: 32575361, PMCID: PMC7345993, DOI: 10.3390/metabo10060257.Peer-Reviewed Original ResearchColorectal cancerAnatomic locationTissue-specific biomarkersOrthogonal partial least squares discriminant analysisBlood samplesMetabolite biomarkersTumor tissueRight-sided colon cancerPatient blood samplesCRC patientsStudy cohortScreening regimensIndependent cohortUntargeted metabolomics analysisStage IColon cancerDisease influenceMetabolic consequencesDiscriminatory biomarkersNormal colonMetabolic signaturesPre-validation phaseBiomarker studiesBiomarkersCancer
2019
Molecular Pathway Analysis Indicates a Distinct Metabolic Phenotype in Women With Right-Sided Colon Cancer
Sun Y, Mironova V, Chen Y, Lundh EPF, Zhang Q, Cai Y, Vasiliou V, Zhang Y, Garcia-Milian R, Khan SA, Johnson CH. Molecular Pathway Analysis Indicates a Distinct Metabolic Phenotype in Women With Right-Sided Colon Cancer. Translational Oncology 2019, 13: 42-56. PMID: 31760268, PMCID: PMC6883319, DOI: 10.1016/j.tranon.2019.09.004.Peer-Reviewed Original ResearchRight-sided colon cancerLeft-sided colon cancerColon cancerAnatomical locationTumor tissueAnti-tumor immune responseGene Expression OmnibusImportant predictive markerPoor clinical outcomeTumor anatomical locationClinical outcomesPredictive markerPrimary tumorImmune phenotypeDistinct metabolic phenotypesImmune responseLower incidenceTreatment responseSex-specific differencesMolecular pathway analysisClinical importanceCancerProtein kinase alpha subunitBiotechnology Information Gene Expression OmnibusWomen
2016
EGFR Gene Amplification and KRAS Mutation Predict Response to Combination Targeted Therapy in Metastatic Colorectal Cancer
Khan SA, Zeng Z, Shia J, Paty PB. EGFR Gene Amplification and KRAS Mutation Predict Response to Combination Targeted Therapy in Metastatic Colorectal Cancer. Pathology & Oncology Research 2016, 23: 673-677. PMID: 28025786, PMCID: PMC5451302, DOI: 10.1007/s12253-016-0166-2.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Agents, ImmunologicalAntineoplastic Agents, PhytogenicAntineoplastic Combined Chemotherapy ProtocolsBevacizumabBiomarkers, TumorCamptothecinCetuximabColorectal NeoplasmsDNA Mutational AnalysisErbB ReceptorsFemaleGene AmplificationGenes, p53HumansIrinotecanMaleMiddle AgedMutationRas ProteinsConceptsCombination biologic therapyMetastatic colorectal cancerIrinotecan-refractory colorectal cancerRefractory colorectal cancerColorectal cancerEGFR gene amplificationBiologic therapyKRAS mutationsIrinotecan-refractory metastatic colorectal cancerRefractory metastatic colorectal cancerCombination Targeted TherapyGene amplificationPhase II trialEGFR copy numberII trialPredictive biomarkersPredictive markerTargeted therapyTreatment responseBRAF mutationsBevacizumabPatientsCetuximabTumor tissueTherapy